NL-OMON21758
尚未招募
不适用
Phase 0 proof of concept study: a clinical pharmacokinetic microdosing trial with gemcitabine
Antoni van Leeuwenhoek hospital0 个研究点目标入组 10 人待定
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Antoni van Leeuwenhoek hospital
- 入组人数
- 10
- 状态
- 尚未招募
- 最后更新
- 2年前
概览
简要总结
one
研究者
入排标准
入选标准
- •1\.Age \> 18 years.
- •2\.Indication for treatment with gemcitabine.
排除标准
- •Subjects will not be eligible for study entry if any of the following criteria are met:
- •1\.Prior chemotherapy, radiotherapy, radio immunotherapy, or immunotherapy within 7 days of the first dose of study treatment
结局指标
主要结局
未指定
相似试验
已完成
不适用
Phase 0 proof of concept study: a clinical pharmacokinetic microdosing trial with gemcitabinemetastatic bladder cancer and malignant mesotheliomaMetastatic non-small cell lung cancer10027655NL-OMON45398Antoni van Leeuwenhoek Ziekenhuis10
已完成
不适用
A Study of Cediranib and Olaparib at Disease Worsening in Ovarian CancerOvarian CancerNCT02681237University Health Network, Toronto34
已完成
2 期
Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to RavulizumabParoxysmal Nocturnal HemoglobinuriaNCT05972967Omeros Corporation12
已完成
不适用
Studying the safety and the pharmacokinetics after single dosing of KDF2001 in healthy adultEndocrine, nutritional and metabolic diseasesKCT0009163Kyung Dong Pharmaceutical40
招募中
1 期
Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal HemoglobinuriaNCT05889299Omeros Corporation10